Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1989 Jun 24;298(6689):1684–1686. doi: 10.1136/bmj.298.6689.1684

Inhibin: a new circulating marker of hydatidiform mole?

T Yohkaichiya 1, T Fukaya 1, H Hoshiai 1, A Yajima 1, D M de Kretser 1
PMCID: PMC1836764  PMID: 2503176

Abstract

OBJECTIVE--To define the concentrations of inhibin in serum and tissue of patients with hydatidiform mole and assess their value as a clinical marker of the condition. DESIGN--Prospective study of new patients with hydatidiform mole, comparison of paired observations, and case-control analysis. SETTING--A university hospital, two large public hospitals, and a private women's clinic in Japan. PATIENTS--Seven consecutive referred patients seen over four months with newly diagnosed complete hydatidiform mole, including one in whom the mole was accompanied by viable twin fetuses (case excluded from statistical analysis because of unique clinical features). All patients followed up for six months after evacuation of molar tissue. END POINT--Correlation of serum inhibin concentrations with trophoblastic disease. MEASUREMENTS AND MAIN RESULTS--Serum concentrations of inhibin, human chorionic gonadotrophin, and follicle stimulating hormone were compared before and seven to 10 days after evacuation of the mole. Before evacuation the serum inhibin concentrations (median 8.3 U/ml; 95% confidence interval 2.4 to 34.5) were significantly greater than in 21 normal women at the same stage of pregnancy (2.8 U/ml; 2.1 to 3.6), and inhibin in molar tissue was also present in high concentrations (578 U/ml cytosol; 158 to 1162). Seven to 10 days after evacuation inhibin concentrations in serum samples from the same patients declined significantly to values (0.4 U/ml; 0.1 to 1.4) similar to those seen in the follicular phase of normal menstrual cycles. None of the four patients whose serum inhibin concentrations were 0.4 U/ml or less after evacuation developed persistent trophoblastic disease. Though serum human chorionic gonadotrophin concentrations declined after evacuation (6.6 x 10(3) IU/l; 0.8 x 10(3) to 32.6 x 10(3], they remained far higher than in non-pregnant women. Serum follicle stimulating hormone concentrations remained suppressed. CONCLUSIONS--In this small study serum inhibin concentrations higher than those found in the early follicular phase one to two weeks after evacuation of a hydatidiform mole seemed to be specific for persistent trophoblastic disease. Further data are needed to confirm these promising results.

Full text

PDF
1684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DuBeshter B., Berkowitz R. S., Goldstein D. P., Cramer D. W., Bernstein M. R. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol. 1987 Mar;69(3 Pt 1):390–395. [PubMed] [Google Scholar]
  2. HOBSON B. M. Further observations on the excretion of chorionic gonadotrophin by women with hydatidiform mole. J Obstet Gynaecol Br Emp. 1958 Apr;65(2):253–259. doi: 10.1111/j.1471-0528.1958.tb09193.x. [DOI] [PubMed] [Google Scholar]
  3. Mayo K. E., Cerelli G. M., Spiess J., Rivier J., Rosenfeld M. G., Evans R. M., Vale W. Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci U S A. 1986 Aug;83(16):5849–5853. doi: 10.1073/pnas.83.16.5849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. McLachlan R. I., Healy D. L., Robertson D. M., Burger H. G., de Kretser D. M. Circulating immunoactive inhibin in the luteal phase and early gestation of women undergoing ovulation induction. Fertil Steril. 1987 Dec;48(6):1001–1005. doi: 10.1016/s0015-0282(16)59599-5. [DOI] [PubMed] [Google Scholar]
  5. McLachlan R. I., Healy D. L., Robertson D. M., Burger H. G., de Kretser D. M. The human placenta: a novel source of inhibin. Biochem Biophys Res Commun. 1986 Oct 30;140(2):485–490. doi: 10.1016/0006-291x(86)90758-8. [DOI] [PubMed] [Google Scholar]
  6. McLachlan R. I., Robertson D. M., Healy D. L., Burger H. G., de Kretser D. M. Circulating immunoreactive inhibin levels during the normal human menstrual cycle. J Clin Endocrinol Metab. 1987 Nov;65(5):954–961. doi: 10.1210/jcem-65-5-954. [DOI] [PubMed] [Google Scholar]
  7. Petraglia F., Sawchenko P., Lim A. T., Rivier J., Vale W. Localization, secretion, and action of inhibin in human placenta. Science. 1987 Jul 10;237(4811):187–189. doi: 10.1126/science.3299703. [DOI] [PubMed] [Google Scholar]
  8. Robertson D. M., Foulds L. M., Leversha L., Morgan F. J., Hearn M. T., Burger H. G., Wettenhall R. E., de Kretser D. M. Isolation of inhibin from bovine follicular fluid. Biochem Biophys Res Commun. 1985 Jan 16;126(1):220–226. doi: 10.1016/0006-291x(85)90594-7. [DOI] [PubMed] [Google Scholar]
  9. Robertson D. M., Tsonis C. G., McLachlan R. I., Handelsman D. J., Leask R., Baird D. T., McNeilly A. S., Hayward S., Healy D. L., Findlay J. K. Comparison of inhibin immunological and in vitro biological activities in human serum. J Clin Endocrinol Metab. 1988 Sep;67(3):438–443. doi: 10.1210/jcem-67-3-438. [DOI] [PubMed] [Google Scholar]
  10. Schlaerth J. B., Morrow C. P., Kletzky O. A., Nalick R. H., D'Ablaing G. A. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol. 1981 Oct;58(4):478–482. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES